Hikma Recalls Ciprofloxacin Tablets Due to Nitrosamine Contamination
Hikma Pharmaceuticals is recalling 20,335 bottles of Ciprofloxacin 750 mg tablets because N-nitroso-ciprofloxacin levels exceeded FDA limits.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II due to N-nitroso-ciprofloxacin levels exceeding FDA interim control limits. The source does not report any illnesses, injuries, or deaths.
Plain-English summary
Hikma Pharmaceuticals USA Inc. is recalling 20,335 bottles of Ciprofloxacin Tablets, USP, 750 mg. The affected product is distributed nationwide in the United States. The recall involves three specific lots: CA083A, CA084A, and CA085A, all with an expiration date of 12/31/2026. The product is identified by NDC 0143-9929-50.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, testing revealed that N-nitroso-ciprofloxacin results were above the FDA recommended interim control limit. N-nitrosamines are potential carcinogens that are strictly regulated in pharmaceutical products.
Consumers who have purchased these specific lots should stop using the medication and contact their healthcare provider for guidance on alternative treatment. The source text does not report any illnesses, injuries, or deaths associated with this recall.
The recalled product
- Product
- CIPROFLOXACIN (CIPROFLOXACIN)
- Brand
- CIPROFLOXACIN
- Manufacturer
- Hikma Pharmaceuticals USA INC.
- Category
- Drug — Antibiotic
- Affected units
- 20,335
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CIPROFLOXACIN
- SevereHikma Recalls Ciprofloxacin Tablets Due to Nitrosamine Contamination
FDA (Drugs) · 2026-11-11
- ModerateCiprofloxacin Ophthalmic Solution Recalled Nationwide for Defective Container Cap
FDA (Drugs) · 2025-03-26
- HighCiprofloxacin Ophthalmic Eye Drops Recalled Due to Defective Container
FDA (Drugs) · 2025-01-15
- ModerateCiprofloxacin Ophthalmic Solution Recalled Due to Defective Container
FDA (Drugs) · 2024-08-07
- ModerateCiprofloxacin Tablets Recalled for Foreign Material Presence
FDA (Drugs) · 2013-04-03
Same manufacturer · Hikma Pharmaceuticals USA INC.
See all →- ModerateHikma Recalls Abirtega Tablets for Weight Uniformity Failures
FDA (Drugs) · 2026-10-28
- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateAlendronate Sodium Oral Solution Recalled for Out-of-Specification Assay Results
FDA (Drugs) · 2026-05-06
- ModerateLorazepam injection vials failed the total related compounds impurity specification
FDA (Drugs) · 2025-08-06
- SevereFDA Recalls Acetaminophen Injection Due to Labeling Mix-up
FDA (Drugs) · 2024-08-28
Same hazard · nitrosamine contamination
See all →- SeverePerrigo Recalls Ranitidine Tablets Due to Potential N-Nitrosodimethylamine Contamination
FDA (Drugs) · 2020-03-25
- SeverePerrigo Recalls Ranitidine Tablets Due to Potential N-Nitrosodimethylamine Contamination
FDA (Drugs) · 2020-03-25
- SeverePerrigo Recalls Ranitidine Tablets Due to Potential N-Nitrosodimethylamine Contamination
FDA (Drugs) · 2020-03-25
- SeverePerrigo Recalls Ranitidine Tablets Due to Potential N-Nitrosodimethylamine Contamination
FDA (Drugs) · 2020-03-25
- SeverePerrigo Recalls Ranitidine Tablets Due to Possible N-Nitrosodimethylamine Contamination
FDA (Drugs) · 2020-03-25
Similar recalls
- SevereHikma Recalls Ciprofloxacin Tablets Due to Nitrosamine Contamination
FDA (Drugs) · 2026-11-11
- HighCinacalcet 30 mg tablets recalled over a nitrosamine impurity above limits
FDA (Drugs) · 2025-12-17
- SevereCinacalcet 60 mg tablets recalled over a nitrosamine impurity above limits
FDA (Food) · 2025-12-17
- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCinacalcet 90 mg tablets recalled over a nitrosamine impurity above limits
FDA (Drugs) · 2025-12-17
- HighCipla cinacalcet 30 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22